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In just over one decade since it was first isolated from the
hearts of spontaneously hypertensive rats, much has been
learned about the actions of the soluble 12-kd protein
myotrophin (1). Although ubiquitous, the cardiac effects of
myotrophin have remained the focus of research over this
period (2–8). Myotrophin stimulates protein synthesis in
cardiomyocytes (and hypertrophy of these cells), as well as
the expression of a number of cardiac genes (e.g., beta-
myosin heavy chain and atrial natriuretic peptide) and
proto-oncogenes (e.g., c-myc, c-fos, and c-jun) (2–8).
Myotrophin has similar hypertrophic effects in skeletal
muscle cells (9). Myotrophin appears to bring about this
effects by interacting with nuclear factor-kappa B (NF-
kappa B) (2–8). Indeed, myotrophin has a close structural
homology for inhibitory-kappa B (I-kappa B), a regulatory
peptide controlling the activity of NF-kappa B (2–8).
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Sometime ago Sil et al. (10) found that myotrophin levels
are increased in the hearts of patients with dilated cardio-
myopathy (the etiology is not stated in their report).
Although it is considered a cytosolic protein, O’Brien et al.
(11), in this issue of the Journal, have now shown that
myotrophin circulates in the blood of healthy subjects and
patients with chronic heart failure (CHF), regardless of
whether the etiology is ischemic or nonischemic. Plasma
concentrations of myotrophin were higher in patients than
in control subjects but, curiously, were inversely related to
clinical severity (i.e., patients with higher New York Heart
Association functional class CHF had lower myotrophin
concentrations). Men with CHF also had higher myotro-
phin levels than women with CHF.
These recent observations raise many new questions
about myotrophin in CHF. What is the source of circulat-
ing myotrophin in CHF? As cardiac hypertrophy tends to
increase with increasing severity of CHF (and tends to be
greater in women than in men [12]), perhaps the heart is
not the origin. Skeletal muscle is an alternative source.
Skeletal muscle mass tends to be lower in women than in
men and may reduce as CHF advances (e.g., with the
development of cachexia) (13). The disconnect between
plasma atrial natriuretic peptide (ANP) and myotrophin
concentrations also argues against a cardiac origin (given
that myotrophin stimulates ANP expression in cardiomyo-
cytes) (14).
Alternatively, if the heart is the source of myotrophin,
then these new findings may be describing something very
unusual in CHF—that is, the decline or exhaustion of a
potential “compensatory” mechanism in this condition.
Without exception, other candidate compensatory re-
sponses are persistently activated in CHF and are more
activated in more severely ill patients. If the present findings
indicate that cardiac myotrophin production declines as
CHF advances (or might it be that CHF advances because
myotrophin production declines?), this could be of great
clinical and therapeutic significance. The present findings
may also be very important if they are telling us something
new about the origin of skeletal muscle dysfunction and
wasting in CHF, the latter being of ominous prognostic
significance (13).
Another obvious question raised by the observations of
O’Brien et al. (11) is: what, if any, role does circulating
myotrophin have? Is it just a marker of muscle production or
does it act as a hormone in its own right, in the conventional
sense? Of course, we have assumed plasma concentrations of
myotrophin reflect tissue production, whereas these may
equally reflect reduced clearance, the mechanisms of which
are unknown.
Clearly we need to learn much more about myotrophin in
CHF and, in particular, the cardiac production of this
peptide during the progression of CHF.
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